Hepatitis c virus inhibitors

Abstract

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

What is claimed is: 
     
         1 . A compound selected from:
 dimethyl ((R,S,R,1S,1′S)-((2S,2′S,5S,5′S)-5,5′-(5,5′-([1,1′-biphenyl]-4,4′-diyl)bis(1H-imidazole-5,2-diyl))bis(2-methylpyrrolidine-5,1-diyl))bis(1-(2R,4R,6S)-2-cyclopropyl-6-methyltetrahydro-2H-pyran-4-yl)-2-oxoethane-2,1-diyl))dicarbamate;   dimethyl ((S,R,R,1S,1′S)-((2 S,2′S,5S,5′S)-5,5′-(5,5′-([1,1′-biphenyl]-4,4′-diyl)bis(1H-imidazole-5,2-diyl))bis(2-methylpyrrolidine-5,1-diyl))bis(1-((2S,4R,6R)-2-cyclopropyl-6-methyltetrahydro-2H-pyran-4-yl)-2-oxoethane-2,1-diyl))dicarbamate;   dimethyl ((S,R,S,1S,1′S)-((2S,2′S,5S,5′S)-5,5′-(5,5′-([1,1′-biphenyl]-4,4′-diyl)bis(1H-imidazole-5,2-diyl))bis(2-methylpyrrolidine-5,1-diyl))bis(1-(2R,4S,6S)-2-cyclopropyl-6-methyltetrahydro-2H-pyran-4-yl)-2-oxoethane-2,1-diyl))dicarbamate;   dimethyl (4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((2S,5S)-5-methyl-2,1-pyrrolidinediyl)(1-(3-cyano-3-methylcyclobutylidene)-2-oxo-2,1-ethanediyl)))biscarbamate; and   dimethyl (4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((2S,5S)-5-methyl-2,1-pyrrolidinediyl)(1-(3-cyano-3-methylcyclobutylidene)-2-oxo-2,1-ethanediyl)))biscarbamate;   
       or a pharmaceutically acceptable salt thereof. 
     
     
         2 . A compound selected from:
 dimethyl (4,4′-biphenyldiylbis(1H-imidazole-5,2-diyl((2S,5R)-5-ethynyl-2,1-pyrrolidinediyl)((1S)-1-((2R,6R)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-2-oxo-2,1-ethanediyl)))biscarbamate;   dimethyl (4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((2S,5S)-5-ethynyl-2,1-pyrrolidinediyl)((1S)-1-((2R,6R)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-2-oxo-2,1-ethanediyl)))biscarbamate;   dimethyl (4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((2S,5R)-5-(hydroxymethyl)-2,1-pyrrolidinediyl)((1S)-1-((2R,6R)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-2-oxo-2,1-ethanediyl)))biscarbamate;   dimethyl (4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((2S,5R)-5-(hydroxymethyl)-2,1-pyrrolidinediyl)((1S)-1-((2R,6R)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-2-oxo-2,1-ethanediyl)))biscarbamate;   dimethyl (4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl(3S)-2-azaspiro[4.4]nonane-3,2-diyl((1 S)-1-((2R,6R)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-2-oxo-2,1-ethanediyl)))biscarbamate; and   dimethyl (4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((2S,4R)-4-(cyclopropylmethyl)-2,1-pyrrolidinediyl)((1S)-1-((2R,6R)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-2-oxo-2,1-ethanediyl)))biscarbamate;   
       or a pharmaceutically acceptable salt thereof. 
     
     
         3 . A compound selected from:
 dimethyl (4,4′-biphenyldiylbis(1H-imidazole-5,2-diyl((2S,5S)-5-methyl-2,1-pyrrolidinediyl)((1S)-1-(2-oxaspiro[3.3]hept-6-yl)-2-oxo-2,1-ethanediyl)))biscarbamate;   dimethyl (4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((2S,5S)-5-methyl-2,1-pyrrolidinediyl)((1 S)-1-((2R,4R,4aS,7aS)-2-methyloctahydrocyclopenta[b]pyran-4-yl)-2-oxo-2,1-ethanediyl)))biscarbamate; and   dimethyl (4,4′-biphenyldiylbis(1H-imidazole-4,2-diyl((2S,5S)-5-methyl-2,1-pyrrolidinediyl)((1S)-1-((2R,4S,4aS,7aS)-2-methyloctahydrocyclopenta[b]pyran-4-yl)-2-oxo-2,1-ethanediyl)))biscarbamate;   
       or a pharmaceutically acceptable salt thereof. 
     
     
         4 . A compound which is
 dimethyl ((R,S,S,1 S, 1′S)-((2S,2′S,5S,5′S)-5,5′-(5,5′-([1,1′-biphenyl]-4,4′-diyl)bis(1H-imidazole-5,2-diyl))bis(2-methylpyrrolidine-5,1-diyl))bis(1-((2S,4S,6R)-2-cyclopropyl-6-methyltetrahydro-2H-pyran-4-yl)-2-oxoethane-2,1-diyl))dicarbamate;   
       or a pharmaceutically acceptable salt thereof. 
     
     
         5 . A composition comprising a compound of  claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
     
     
         6 . The composition of  claim 5  further comprising at least one additional compound having anti-HCV activity. 
     
     
         7 . A composition comprising a compound of  claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
     
     
         8 . The composition of  claim 7  further comprising at least one additional compound having anti-HCV activity. 
     
     
         9 . A composition comprising a compound of  claim 3 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
     
     
         10 . The composition of  claim 9  further comprising at least one additional compound having anti-HCV activity. 
     
     
         11 . A composition comprising a compound of  claim 4 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
     
     
         12 . The composition of  claim 11  further comprising at least one additional compound having anti-HCV activity. 
     
     
         13 . A method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of a compound of  claim 1 , or a pharmaceutically acceptable salt thereof. 
     
     
         14 . A method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of a compound of  claim 2 , or a pharmaceutically acceptable salt thereof. 
     
     
         15 . A method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of a compound of  claim 3 , or a pharmaceutically acceptable salt thereof. 
     
     
         16 . A method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of a compound of  claim 4 , or a pharmaceutically acceptable salt thereof.